BCM
LTRN icon

BIOS Capital Management’s Lantern Pharma LTRN Stock Holding History

BIOS Capital Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Sell
864,435
-145,072
-14% -$406K 2.24% 5
2025
Q4 		$3.06M Sell
1,009,507
-6,208
-0.6% -$23.1K 3.7% 4
2025
Q3 		$4.42M Sell
1,015,715
-60,237
-6% -$251K 4.97% 4
2025
Q2 		$3.4M Sell
1,075,952
-131,757
-11% -$445K 4.68% 3
2025
Q1 		$4.28M Hold
1,207,709
– – 5.4% 2
2024
Q4 		$3.85M Buy
+1,207,709
New +$4.14M 4.09% 4

Other funds holding LTRN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

BIOS Capital Management's LTRN Position: Q1 2026 in Review

BIOS Capital Management reduced its Lantern Pharma (LTRN) stake by 14% in Q1 2026, selling an estimated $406K and leaving 864,435 shares worth $1.18M. The position accounts for 2.24% of the portfolio, ranked #5.

BIOS Capital Management first reported a position in LTRN in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.42M in Q3 2025. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • BIOS Capital Management held 864,435 shares of Lantern Pharma worth $1.18M as of Q1 2026.
  • BIOS Capital Management sold 145,072 Lantern Pharma shares in Q1 2026, an estimated $406K.
  • Lantern Pharma made up 2.24% of BIOS Capital Management's portfolio in Q1 2026, its #5 holding.
  • BIOS Capital Management first reported a position in Lantern Pharma in Q4 2024 and has held it in 6 quarters since.
  • BIOS Capital Management's Lantern Pharma position peaked at $4.42M in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on BIOS Capital Management's 13F filing for Q1 2026, filed 13 May 2026.